NewAmsterdam Pharma Company N.V. (NAMSW)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
NewAmsterdam Pharma Company N.V. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SRB Steve R. Bailey Frazier Life Sciences Management LP | 500,333 | $434,289.04 | $12.45M | $12.02M | 2,767.51% |
NewAmsterdam Pharma Company N.V. (NAMSW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has NewAmsterdam Pharma Company N.V. ever had a stock split?
NewAmsterdam Pharma Company N.V. Profile
| Biotechnology Industry | Healthcare Sector | Michael Harvey Davidson Facp. CEO | NASDAQ (NMS) Exchange | NL00150012K9 ISIN |
| NL Country | 68 Employees | - Last Dividend | 23 Nov 2022 Last Split | 23 Nov 2022 IPO Date |
Overview
NewAmsterdam Pharma Company N.V. operates as a late-stage biopharmaceutical entity specializing in the development of innovative therapeutic solutions aimed at enhancing patient care within metabolic disease populations. The company, which is based in Naarden, the Netherlands, leverages advanced science and technology to address unmet needs in cardiovascular diseases and potentially in Alzheimer's disease. Through its commitment to research and development, NewAmsterdam Pharma Company N.V. is at the forefront of discovering and advancing novel treatment options for patients worldwide.
Products and Services
- Obicetrapib as Monotherapy and Combination Therapy with Ezetimibe
This product is centered on obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor. Currently, in various stages of clinical trials, obicetrapib is being evaluated both as a standalone therapy and in combination with ezetimibe. The main aim of these treatments is to lower LDL-C levels, which is a crucial factor in the management and prevention of cardiovascular diseases. This development indicates the company's focus on cardiovascular health and its potential to offer a new option in the lipid management landscape.
- Obicetrapib for Alzheimer's Disease
Also in the pipeline is the exploration of Obicetrapib's effects on Alzheimer's disease, with the drug currently undergoing a Phase 2a clinical trial. This investigation into its utility for treating Alzheimer's disease highlights NewAmsterdam Pharma Company N.V.’s commitment to expanding its research and therapeutic applications beyond cardiovascular health, potentially offering hope for patients and families affected by Alzheimer's disease.
